Vaccine Adjuvants Market Trends

Growth Drivers

• Rising Number of Government Initiatives to Promote Vaccination and Support the Development of New Vaccines - For instance, a National Strategic Plan (2021-2025) for vaccines and immunizations provide a vision for the future of the U.S. vaccine and immunization enterprise. US Healthy People 2030 initiative focuses on increasing vaccination rates to prevent infectious diseases. This initiative seeks to increase public awareness around the importance of vaccination and its role in the prevention of infectious diseases. Moreover, Indian government's vaccination initiatives such as Har Ghar Dastak and Jan Bhagidari Andolan have been successful in immunizing large sections of the population, especially in rural areas where access to healthcare is scarce. As a result, there has been a significant reduction in the prevalence of vaccine-preventable diseases.
• Growing Cases of Seasonal Influenza - Seasonal influenza causes between -3 million and 5 million severe illnesses and between 290,000 and 650,000 respiratory deaths per year, according to the World Health Organization. As the number of influenza cases increase, so does the need for more effective influenza vaccines. Vaccine adjuvants are substances added to vaccines to enhance their effectiveness, making them better able to protect against the virus.
• Increase in the Number of HIV/AIDS Cases - According to the Centers for Disease Control and Prevention (CDC), there were an estimated 1,189,700 HIV-positive individuals in the United States as of the end of 2019. HIV is most prevalent among black and African American people. The number of new HIV diagnoses among Black/African American people in 2020 was 42 percent (12,827).
• High Prevalence Chronic Diseases Such as Cancer have Prompted a Surge in the Demand for Vaccine Adjuvants- Vaccine adjuvants are used to enhance the body's immune response to the cancer cells, allowing the body to mount a stronger attack against the cancer cells. This can help to reduce the growth of the tumor and even eliminate it altogether. Thus, the rising prevalence of cancer is expected to drive vaccine adjuvants market growth. The World Health Organization estimates that cancer caused nearly 10 million deaths worldwide in 2020. Among the most common cancers are breast, lung, colon, and rectum cancers as well as prostate cancer.
• Increasing Development and Approval of Several COVID-19 Vaccines - For instance, Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 in individuals 18 years of age and older, was approved by the United States Food and Drug Administration in July 2022 as an emergency use authorization (EUA).

Challenges

• Long approval process - Vaccines are heavily regulated, and the approval process can be lengthy and complex. This can delay the availability of new vaccines and even cause existing vaccines to be taken off the vaccine adjuvants market. The lengthy approval process can also make it difficult for new companies to enter the market.
• High cost of vaccine adjuvants
• Complexities associated with the development of vaccine adjuvants, as well as stringent regulatory requirements